EBMT NEWSLETTER | November 2015 | Volume 49 - Issue 1

Important dates

EBMT Publications

Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties.
Penack O, Tridello G, Hoek J, Socié G, Blaise D, Passweg J, Chevallier P, Craddock C, Milpied N, Veelken H, Maertens J, Ljungman P, Cornelissen J, Thiebaut-Bertrand A, Lioure B, Michallet M, Iacobelli S, Nagler A, Mohty M, Cesaro S.
Bone Marrow Transplant. 2015 Oct 26. doi: 10.1038/bmt.2015.237. [Epub ahead of print]

In this retrospective study of the Infectious Disease Working Party in collaboration with the Acute Leukemia Working Party the investigators analyzed the impact of  prior invasive fungal infection on outcome after allogeneic stem cell transplantation. They analyzed 1150 patients with acute leukemia and data on previous invasive fungal infection. Interestingly, the authors found no significant difference in NRM, Relapse and survival of patients with or without prior invasive fungal infection. In contrast to smaller studies, which suggested a negative impact of prior invasive fungal infection, the results of this very large cohort of patients suggested that patients with prior invasive fungal infection should not be excluded from allogeneic stem cell transplantation. Unfortunately, from the reported data in the registry it was not clear whether the prior fungal infection was resolved or still ongoing at time of transplant, therefore, the authors are now planning a prospective study.
Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation.
Marchand T, Lamy T, Finel H, Arcese W, Choquet S, Finke J, Huynh A, Irrera G, Karakasis D, Konopacki J, Lambert J, Michieli M, Schouten HC, Schroyens W, Sucak G, Tischer J, Vandenberghe E, Dreger P.
Leukemia. 2015 Sep 22. doi: 10.1038/leu.2015.256. [Epub ahead of print]
Large granular lymphocyte (LGL) leukemia is a rare lymphoproliferative disorder characterized by clonal expansion of either CD3+ cytotoxic T-lymphocytes or CD3 NK cells.
A total of 33 patients fulfilling the inclusion criteria were identified in the EBMT registry (allo-HSCT 20 and auto-HSCT 13) but only in 15 patients, the requested additional data could be retrieved and the diagnosis of LGL finally confirmed in all (allo-HSCT 10, auto-HSCT 5). From 10 allogeneic transplanted patients, five patients are still alive and in remission after a median follow-up of 30 months, resulting into a 2-year PFS and OS of 50% each. From 5 autologous transplanted patients, two remain alive and disease-free 27 and 52 months post auto-HSCT, respectively. Despite the small number of patients included, the results provide first evidence of hematopoietic stem cell transplantation as a potential curative option in rare aggressive and relapsing forms of T-LGL leukemia
European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Boztug H, Sykora KW, Slatter M, Zecca M, Veys P, Lankester A, Cant A, Skinner R, Wachowiak J, Glogova E, Pötschger U, Peters C.
Pediatr Blood Cancer. 2015 Sep 23. doi: 10.1002/pbc.25764. [Epub ahead of print]
In a recent report of the Pediatric Disease Working Party encouraging results of treosulfan as conditioning regimen has been reported for non–malignant diseases. Here, the Pediatric  Disease Working Party reported the results of treosulfan as part of the conditioning regimen in children and adolescents with hematological malignancies. They included 193 children with ALL (n = 71), AML (n = 47), MDS/MPS ( n = 40) and other leukemia/lymphoma (n = 25)
Regimen-related toxicity was low and mainly gastrointestinal. There was no association of toxicity with type of disease or treosulfan dose. High-grade early toxicity was not higher in infants or patients undergoing second or later transplantation. Treatment related mortality was low at 14%. Three-year event-free survival was 45 ± 4% and not significantly influenced by number of transplants, however it appeared to be significantly better for infants (P = 0.022). When compared to treosulfan plus fludarabine, the combination of treosulfan, fludarabine and an alkylator (either thiotepa or melphalan) resulted in significantly better overall survival (OS, P = 0.048) and a trend toward better EFS.
This results confirmed the low toxicity profile and high anti-leukemic activity of treosulfan , especially if it is combned with another alkylating agent.

View all the EBMT publications on the website

BMT Journal featured articles

Bone Marrow Transplantation publishes high quality, peer reviewed original research and reviews that address all aspects of basic biology and clinical use of haemopoietic cell transplantation.
The journal also covers all aspects of the research and treatment of transplant-related complications and consequences including quality of life and psychological issues. Basic research studies on topics of relevance are also covered.
2014 Impact Factor 3.570*
*2014 Journal Citation Reports® Science Edition (Thomson Reuters, 2015)
Average time to first decision = 10 days
Average time to online publication  = 24 days
Open Access option
High visibility via nature.com – 1.5million page views in 2015
Have you read the below recently trending articles…
Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation
H Nakasone, T Fukuda et al
Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective
F Saraceni, N Shem-Tov et al
Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants
J R Passweg, H Baldomero et al
Fecal microbiota transplant after hematopoietic SCT: report of a successful case
C G de Castro Jr, A J Ganc et al.
Umbilical cord blood donation: public or private?
K K Ballen, F Verter & J Kurtzberg
Get your research the recognition it deserves - Submit to BMT TODAY

Bookmark and Share